X

The ASCO Post

The ASCO Post
Weekly Outpatient Palliative Care Interventions Among Patients With Head and Neck Cancer

Over 90% of patients with head and neck cancer receiving curative-intent chemoradiation therapy found weekly palliative care visits to be a valuable addition to their treatment.

The ASCO Post
07/27/2021
Overall Survival Benefit Reported With Daratumumab Plus Lenalidomide in Myeloma

The addition of the monoclonal antibody daratumumab to the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone significantly improves OS over lenalidomide/dexamethasone alone..

The ASCO Post
07/25/2021
FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage TNBC

The FDA approves pembrolizumab for high-risk, early-stage TNBC in combination with CT as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

The ASCO Post
07/27/2021
Novel Monoclonal Antibody Emerges as Potential First-Line Standard in Nasopharyngeal Cancer

A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial...

The ASCO Post
07/25/2021
Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better

In advanced ovarian cancer, the duration of maintenance bevacizumab should remain 15 months, according to the European multicenter phase III ENGOT/GCIG trial.

The ASCO Post
07/25/2021
FDA Grants Regular Approval to Pembrolizumab/Lenvatinib for Advanced Endometrial Carcinoma

The FDA approves pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not MSI-H or dMMR who have disease progression following...

The ASCO Post
07/22/2021
Breast-Conserving Surgery Plus Radiotherapy May Yield Better Survival Than Mastectomy With or Without Radiotherapy

de Boniface et al find that breast-conserving surgery plus RT for women with breast cancer is associated with better survival vs mastectomy with or without RT in analysis adjusting for...

The ASCO Post
07/21/2021
Addition of AKT Inhibitor Ipatasertib to Abiraterone/Prednisolone in mCRPC With PTEN Loss

Study investigators find that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produces a significant improvement in PFS among patients with mCRPC with PTEN loss...

The ASCO Post
07/21/2021
Addition of Prime-Boost Vaccination Regimen to Atezolizumab in Soft-Tissue Sarcomas Expressing NY-ESO-1

Study investigators find that the addition of the heterologous prime-boost vaccination regimen CMB305 to atezolizumab did not improve survival outcomes in patients with STS expressing...

The ASCO Post
07/21/2021
Real-World Survival Outcomes With Pertuzumab Plus T-DM1 for HER2-Positive Metastatic Breast Cancer

Study investigators identify real-world survival outcomes among women receiving pertuzumab and trastuzumab emtansine for stage IV HER2+ breast cancer...

The ASCO Post
07/19/2021
Subscribe to The ASCO Post

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834